Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05821634 · ClinicalTrials.gov registry record · NA

Personalizing Treatment Delivery

A NA study of Anxiety Disorders and Symptoms and PTSD and Trauma-related Symptoms, sponsored by Rutgers, The State University of New Jersey.

Recruiting
Registry status
NA
Development phase
81
Enrollment target
1
Study location

NCT05821634: Recruiting NA study of Anxiety Disorders and Symptoms and PTSD and Trauma-related Symptoms, sponsored by Rutgers, The State University of New Jersey.

NCT05821634 is a NA study of Anxiety Disorders and Symptoms and PTSD and Trauma-related Symptoms that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 81 participants, below the 128-participant average among 9 other Anxiety Disorders and Symptoms trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05821634, a NA study of Anxiety Disorders and Symptoms and PTSD and Trauma-related Symptoms, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.

RECRUITING
Registry status
NA
Development phase
81 participants
Enrollment target
1
Study location

Study Summary

Anxiety and anxiety-related disorders frequently co-occur with alcohol use problems resulting in an enormous humanitarian and economic cost to society. The proposed research will use digital technology to examine person-specific risk factors predicting problematic alcohol use in individuals vulnerable to anxiety and anxiety-related disorders and will use this information to design a personalized intervention for individuals seeking psychological treatment. Results from this research will integrate output from novel and innovative digital technology methods into psychotherapy, advancing research on personalized treatment and prevention efforts.

Conditions Studied

Anxiety Disorders and Symptoms PTSD and Trauma-related Symptoms Alcohol; Use, Problem; Alcohol Use Disorder

Interventions

  • BEHAVIORAL Personalized intervention condition: Cognitive behavioral therapy skills
  • BEHAVIORAL Therapeutic control condition: Cognitive behavioral therapy skills
  • BEHAVIORAL Tracking control condition: Supportive counseling

Study Locations (1)

New Jersey

  • Rutgers Robert Wood Johnson Medical School - Piscataway

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2024-10-21
Est. Completion 2027-04-01
Phase NA
Rutgers, The State University of New Jersey

413 total trials

What NCT05821634 shows while recruiting

NCT05821634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 128-participant average among 9 other Anxiety Disorders and Symptoms trials with a reported enrollment target (37% lower).

The record links to 3 conditions, with Anxiety Disorders and Symptoms appearing as the primary indexed condition, and to 3 interventions - of which Personalized intervention condition: Cognitive behavioral therapy skills is the first listed.

NCT05821634 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT05821634 about?

NCT05821634 is a clinical study titled "Personalizing Treatment Delivery". Anxiety and anxiety-related disorders frequently co-occur with alcohol use problems resulting in an enormous humanitarian and economic cost to society. The proposed research will use digital technology to examine person-specific risk factors predicting problematic alcohol use in individuals vulnerab...

What is the current status of trial NCT05821634?

This trial is currently recruiting. It is a NA study. The enrollment target is 81 participants. The study started on 2024-10-21. Estimated completion is 2027-04-01.

What conditions does trial NCT05821634 study?

This clinical trial studies the following conditions: Anxiety Disorders and Symptoms, PTSD and Trauma-related Symptoms, Alcohol; Use, Problem; Alcohol Use Disorder.

What interventions are being tested in trial NCT05821634?

The interventions under investigation include: Personalized intervention condition: Cognitive behavioral therapy skills (BEHAVIORAL), Therapeutic control condition: Cognitive behavioral therapy skills (BEHAVIORAL), Tracking control condition: Supportive counseling (BEHAVIORAL).

Who is sponsoring clinical trial NCT05821634?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05821634 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anxiety Disorders and Symptoms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05821634's enrollment target sits among peer trials

81 6th of 9 higher than 4 of 9 other Anxiety Disorders and Symptoms trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anxiety Disorders and Symptoms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04966481 · 81 participants · Phase 3

    Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

  • NCT05109429 · 81 participants · NA

    Developing a Clinical Outcome Assessment for Opioid Craving

  • NCT05112601 · 81 participants · Phase 2

    Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  • NCT05305911 · 81 participants · Phase 2

    Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05821634

Source: ClinicalTrials.gov NCT05821634, the US trial registry maintained by the National Library of Medicine. NCT05821634 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.